Both in Pharmaceuticals
Trevi Therapeutics vs Xeris Biopharma Holdings
Over the past year TRVI returned +28.4% and XERS returned +15.3%; their daily moves had a correlation of 0.20.
TRVI +28.4% XERS +15.3%Growth of $1, one year, split-adjusted
| Metric | TRVI | XERS |
|---|---|---|
| Price | $13.52 | $10.64 |
| Market cap | $1.93B | $1.94B |
| Today | +1.27% | +1.82% |
| 1 month | −6.2% | +6.6% |
| 6 months | −2.2% | +76.7% |
| Year to date | +8.0% | +35.5% |
| 1 year | +28.8% | +14.3% |
| Revenue growth (YoY) | — | +28.7% |
| Gross margin | — | 86.4% |
| Net margin | — | −33.8% |
| P/E (TTM) | — | — |
| Price / sales | — | 5.8× |
| Net cash | $318.9M | -$130.8M |
| Dividend yield | — | — |
| Volatility (60d) | 39.2% | 57.0% |
| Short % of float | 14.4% | 4.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).